 | • レポートコード：GIR-23F3841 • 出版社/出版日：GlobalInfoResearch / 2023年2月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、71ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Ivosidenib Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界のイボシデニブの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 イボシデニブ市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・60錠、30錠 アプリケーション別セグメントは次のように区分されます。 ・病院、薬局 世界のイボシデニブ市場の主要なマーケットプレーヤーは以下のとおりです。 ・Agios Pharmaceuticals 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - イボシデニブの概要 - タイプ別分析（2017年vs2021年vs2028年）：60錠、30錠 - アプリケーション別分析（2017年vs2021年vs2028年）：病院、薬局 - 世界のイボシデニブ市場規模・予測 - 世界のイボシデニブ生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Agios Pharmaceuticals ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：60錠、30錠 ・アプリケーション別分析2017年-2028年：病院、薬局 ・イボシデニブの北米市場分析 - イボシデニブの北米市場：タイプ別市場規模2017年-2028年 - イボシデニブの北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・イボシデニブのヨーロッパ市場分析 - ：イボシデニブのヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：イボシデニブのヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・イボシデニブのアジア太平洋市場分析 - イボシデニブのアジア太平洋市場：タイプ別市場規模2017年-2028年 - イボシデニブのアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・イボシデニブの南米市場分析 - イボシデニブの南米市場：タイプ別市場規模2017年-2028年 - イボシデニブの南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・イボシデニブの中東・アフリカ市場分析 - イボシデニブの中東・アフリカ市場：タイプ別市場規模2017年-2028年 - イボシデニブの中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Ivosidenib market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Ivosidenib market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Ivosidenib global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 60 Tablets segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Ivosidenib include Agios Pharmaceuticals, , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Ivosidenib market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
60 Tablets
30 Tablets
Market segment by Application can be divided into
Hospital
Pharmacy
The key market players for global Ivosidenib market are listed below:
Agios Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ivosidenib product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Ivosidenib, with price, sales, revenue and global market share of Ivosidenib from 2019 to 2022.
Chapter 3, the Ivosidenib competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ivosidenib breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Ivosidenib market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Ivosidenib.
Chapter 13, 14, and 15, to describe Ivosidenib sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Ivosidenib Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Ivosidenib Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 60 Tablets
1.2.3 30 Tablets
1.3 Market Analysis by Application
1.3.1 Overview: Global Ivosidenib Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Ivosidenib Market Size & Forecast
1.4.1 Global Ivosidenib Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Ivosidenib Sales in Volume (2017-2028)
1.4.3 Global Ivosidenib Price (2017-2028)
1.5 Global Ivosidenib Production Capacity Analysis
1.5.1 Global Ivosidenib Total Production Capacity (2017-2028)
1.5.2 Global Ivosidenib Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Ivosidenib Market Drivers
1.6.2 Ivosidenib Market Restraints
1.6.3 Ivosidenib Trends Analysis
2 Manufacturers Profiles
2.1 Agios Pharmaceuticals
2.1.1 Agios Pharmaceuticals Details
2.1.2 Agios Pharmaceuticals Major Business
2.1.3 Agios Pharmaceuticals Ivosidenib Product and Services
2.1.4 Agios Pharmaceuticals Ivosidenib Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Ivosidenib Breakdown Data by Manufacturer
3.1 Global Ivosidenib Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Ivosidenib Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Ivosidenib
3.4 Market Concentration Rate
3.4.1 Top 3 Ivosidenib Manufacturer Market Share in 2021
3.4.2 Top 6 Ivosidenib Manufacturer Market Share in 2021
3.5 Global Ivosidenib Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Ivosidenib Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Ivosidenib Market Size by Region
4.1.1 Global Ivosidenib Sales in Volume by Region (2017-2028)
4.1.2 Global Ivosidenib Revenue by Region (2017-2028)
4.2 North America Ivosidenib Revenue (2017-2028)
4.3 Europe Ivosidenib Revenue (2017-2028)
4.4 Asia-Pacific Ivosidenib Revenue (2017-2028)
4.5 South America Ivosidenib Revenue (2017-2028)
4.6 Middle East and Africa Ivosidenib Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Ivosidenib Sales in Volume by Type (2017-2028)
5.2 Global Ivosidenib Revenue by Type (2017-2028)
5.3 Global Ivosidenib Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Ivosidenib Sales in Volume by Application (2017-2028)
6.2 Global Ivosidenib Revenue by Application (2017-2028)
6.3 Global Ivosidenib Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Ivosidenib Sales by Type (2017-2028)
7.2 North America Ivosidenib Sales by Application (2017-2028)
7.3 North America Ivosidenib Market Size by Country
7.3.1 North America Ivosidenib Sales in Volume by Country (2017-2028)
7.3.2 North America Ivosidenib Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Ivosidenib Sales by Type (2017-2028)
8.2 Europe Ivosidenib Sales by Application (2017-2028)
8.3 Europe Ivosidenib Market Size by Country
8.3.1 Europe Ivosidenib Sales in Volume by Country (2017-2028)
8.3.2 Europe Ivosidenib Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Ivosidenib Sales by Type (2017-2028)
9.2 Asia-Pacific Ivosidenib Sales by Application (2017-2028)
9.3 Asia-Pacific Ivosidenib Market Size by Region
9.3.1 Asia-Pacific Ivosidenib Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Ivosidenib Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Ivosidenib Sales by Type (2017-2028)
10.2 South America Ivosidenib Sales by Application (2017-2028)
10.3 South America Ivosidenib Market Size by Country
10.3.1 South America Ivosidenib Sales in Volume by Country (2017-2028)
10.3.2 South America Ivosidenib Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Ivosidenib Sales by Type (2017-2028)
11.2 Middle East & Africa Ivosidenib Sales by Application (2017-2028)
11.3 Middle East & Africa Ivosidenib Market Size by Country
11.3.1 Middle East & Africa Ivosidenib Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Ivosidenib Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Ivosidenib and Key Manufacturers
12.2 Manufacturing Costs Percentage of Ivosidenib
12.3 Ivosidenib Production Process
12.4 Ivosidenib Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Ivosidenib Typical Distributors
13.3 Ivosidenib Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Ivosidenib Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Ivosidenib Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Agios Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Agios Pharmaceuticals Major Business
Table 5. Agios Pharmaceuticals Ivosidenib Product and Services
Table 6. Agios Pharmaceuticals Ivosidenib Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Ivosidenib Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 8. Global Ivosidenib Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Ivosidenib, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Ivosidenib Production Capacity by Company, (K Units): 2020 VS 2021
Table 11. Head Office and Ivosidenib Production Site of Key Manufacturer
Table 12. Ivosidenib New Entrant and Capacity Expansion Plans
Table 13. Ivosidenib Mergers & Acquisitions in the Past Five Years
Table 14. Global Ivosidenib Sales by Region (2017-2022) & (K Units)
Table 15. Global Ivosidenib Sales by Region (2023-2028) & (K Units)
Table 16. Global Ivosidenib Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Ivosidenib Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Ivosidenib Sales by Type (2017-2022) & (K Units)
Table 19. Global Ivosidenib Sales by Type (2023-2028) & (K Units)
Table 20. Global Ivosidenib Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Ivosidenib Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Ivosidenib Price by Type (2017-2022) & (USD/Unit)
Table 23. Global Ivosidenib Price by Type (2023-2028) & (USD/Unit)
Table 24. Global Ivosidenib Sales by Application (2017-2022) & (K Units)
Table 25. Global Ivosidenib Sales by Application (2023-2028) & (K Units)
Table 26. Global Ivosidenib Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Ivosidenib Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Ivosidenib Price by Application (2017-2022) & (USD/Unit)
Table 29. Global Ivosidenib Price by Application (2023-2028) & (USD/Unit)
Table 30. North America Ivosidenib Sales by Country (2017-2022) & (K Units)
Table 31. North America Ivosidenib Sales by Country (2023-2028) & (K Units)
Table 32. North America Ivosidenib Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Ivosidenib Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Ivosidenib Sales by Type (2017-2022) & (K Units)
Table 35. North America Ivosidenib Sales by Type (2023-2028) & (K Units)
Table 36. North America Ivosidenib Sales by Application (2017-2022) & (K Units)
Table 37. North America Ivosidenib Sales by Application (2023-2028) & (K Units)
Table 38. Europe Ivosidenib Sales by Country (2017-2022) & (K Units)
Table 39. Europe Ivosidenib Sales by Country (2023-2028) & (K Units)
Table 40. Europe Ivosidenib Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Ivosidenib Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Ivosidenib Sales by Type (2017-2022) & (K Units)
Table 43. Europe Ivosidenib Sales by Type (2023-2028) & (K Units)
Table 44. Europe Ivosidenib Sales by Application (2017-2022) & (K Units)
Table 45. Europe Ivosidenib Sales by Application (2023-2028) & (K Units)
Table 46. Asia-Pacific Ivosidenib Sales by Region (2017-2022) & (K Units)
Table 47. Asia-Pacific Ivosidenib Sales by Region (2023-2028) & (K Units)
Table 48. Asia-Pacific Ivosidenib Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Ivosidenib Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Ivosidenib Sales by Type (2017-2022) & (K Units)
Table 51. Asia-Pacific Ivosidenib Sales by Type (2023-2028) & (K Units)
Table 52. Asia-Pacific Ivosidenib Sales by Application (2017-2022) & (K Units)
Table 53. Asia-Pacific Ivosidenib Sales by Application (2023-2028) & (K Units)
Table 54. South America Ivosidenib Sales by Country (2017-2022) & (K Units)
Table 55. South America Ivosidenib Sales by Country (2023-2028) & (K Units)
Table 56. South America Ivosidenib Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Ivosidenib Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Ivosidenib Sales by Type (2017-2022) & (K Units)
Table 59. South America Ivosidenib Sales by Type (2023-2028) & (K Units)
Table 60. South America Ivosidenib Sales by Application (2017-2022) & (K Units)
Table 61. South America Ivosidenib Sales by Application (2023-2028) & (K Units)
Table 62. Middle East & Africa Ivosidenib Sales by Region (2017-2022) & (K Units)
Table 63. Middle East & Africa Ivosidenib Sales by Region (2023-2028) & (K Units)
Table 64. Middle East & Africa Ivosidenib Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Ivosidenib Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Ivosidenib Sales by Type (2017-2022) & (K Units)
Table 67. Middle East & Africa Ivosidenib Sales by Type (2023-2028) & (K Units)
Table 68. Middle East & Africa Ivosidenib Sales by Application (2017-2022) & (K Units)
Table 69. Middle East & Africa Ivosidenib Sales by Application (2023-2028) & (K Units)
Table 70. Ivosidenib Raw Material
Table 71. Key Manufacturers of Ivosidenib Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Ivosidenib Typical Distributors
Table 75. Ivosidenib Typical Customers
List of Figures
Figure 1. Ivosidenib Picture
Figure 2. Global Ivosidenib Revenue Market Share by Type in 2021
Figure 3. 60 Tablets
Figure 4. 30 Tablets
Figure 5. Global Ivosidenib Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Pharmacy
Figure 8. Global Ivosidenib Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Ivosidenib Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Ivosidenib Sales (2017-2028) & (K Units)
Figure 11. Global Ivosidenib Price (2017-2028) & (USD/Unit)
Figure 12. Global Ivosidenib Production Capacity (2017-2028) & (K Units)
Figure 13. Global Ivosidenib Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Ivosidenib Market Drivers
Figure 15. Ivosidenib Market Restraints
Figure 16. Ivosidenib Market Trends
Figure 17. Global Ivosidenib Sales Market Share by Manufacturer in 2021
Figure 18. Global Ivosidenib Revenue Market Share by Manufacturer in 2021
Figure 19. Ivosidenib Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Ivosidenib Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Ivosidenib Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Ivosidenib Sales Market Share by Region (2017-2028)
Figure 23. Global Ivosidenib Revenue Market Share by Region (2017-2028)
Figure 24. North America Ivosidenib Revenue (2017-2028) & (USD Million)
Figure 25. Europe Ivosidenib Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Ivosidenib Revenue (2017-2028) & (USD Million)
Figure 27. South America Ivosidenib Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Ivosidenib Revenue (2017-2028) & (USD Million)
Figure 29. Global Ivosidenib Sales Market Share by Type (2017-2028)
Figure 30. Global Ivosidenib Revenue Market Share by Type (2017-2028)
Figure 31. Global Ivosidenib Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Ivosidenib Sales Market Share by Application (2017-2028)
Figure 33. Global Ivosidenib Revenue Market Share by Application (2017-2028)
Figure 34. Global Ivosidenib Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Ivosidenib Sales Market Share by Type (2017-2028)
Figure 36. North America Ivosidenib Sales Market Share by Application (2017-2028)
Figure 37. North America Ivosidenib Sales Market Share by Country (2017-2028)
Figure 38. North America Ivosidenib Revenue Market Share by Country (2017-2028)
Figure 39. United States Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Ivosidenib Sales Market Share by Type (2017-2028)
Figure 43. Europe Ivosidenib Sales Market Share by Application (2017-2028)
Figure 44. Europe Ivosidenib Sales Market Share by Country (2017-2028)
Figure 45. Europe Ivosidenib Revenue Market Share by Country (2017-2028)
Figure 46. Germany Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Ivosidenib Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Ivosidenib Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Ivosidenib Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Ivosidenib Revenue Market Share by Region (2017-2028)
Figure 55. China Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Ivosidenib Sales Market Share by Type (2017-2028)
Figure 62. South America Ivosidenib Sales Market Share by Application (2017-2028)
Figure 63. South America Ivosidenib Sales Market Share by Country (2017-2028)
Figure 64. South America Ivosidenib Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Ivosidenib Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Ivosidenib Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Ivosidenib Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Ivosidenib Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Ivosidenib Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Ivosidenib in 2021
Figure 76. Manufacturing Process Analysis of Ivosidenib
Figure 77. Ivosidenib Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
| 【イボシデニブについて】 イボシデニブ（Ivosidenib）は、抗がん剤として知られる新世代の分子標的治療薬の一つであり、主に急性の白血病や他の悪性腫瘍に対して使用されます。特に、IDH1（イソクエン酸脱水素酵素1）遺伝子の変異に関連する疾患に対して効果的であることが知られています。 イボシデニブは、特に急性幹細胞白血病（AML）において、IDH1変異を持つ患者に対して新しい治療選択肢を提供することが期待されています。IDH1は、細胞のエネルギー代謝に関与する重要な酵素であり、正常な細胞の機能において重要な役割を果たしています。しかしIDH1の遺伝子変異があると、細胞が異常な代謝経路を辿り、がん細胞の発生や進行を引き起こすことがあるのです。 この薬剤は、IDH1変異が細胞内で亜麻酸（2-HG）の蓄積を引き起こすのを阻止します。亜麻酸は、細胞の機能や成長に悪影響を与える代謝中間体であり、がん細胞の生存や増殖を助ける作用があります。イボシデニブは、IDH1によって生成される亜麻酸の生成を阻害することで、がん細胞の増殖を抑制し、最終的には細胞のアポトーシス（プログラムされた細胞死）を誘導します。 イボシデニブの臨床試験結果からは、この薬剤がIDH1変異を持つ急性骨髄性白血病（AML）患者において高い奏効率を示すことが確認されています。また、この薬剤は、通常の化学療法に耐性を示す患者や再発した患者においても効果を発揮することが多いとされています。このように、イボシデニブは、特定の遺伝子変異に基づく個別化医療の一環として、画期的な治療法の一つとされています。 イボシデニブは、経口投与が可能であり、患者にとって利便性が高いこともその特徴の一つです。投与スケジュールは比較的簡便で、患者は自宅で服用することができるため、入院治療の必要がない場合も多くあります。これは、患者の生活の質を向上させる大きな要因となります。 一方で、イボシデニブには副作用も存在します。主な副作用としては、白血球数の減少や肝機能障害、疲労感、悪心（吐き気）、食欲不振などが挙げられます。これらは、治療中の患者の生活に影響を与える可能性があるため、医師は患者の健康状態を継続的に監視し、必要に応じて治療方針を調整する必要があります。特に、肝酵素の異常が見られた場合には、治療の中断や減量が必要となる場合があります。 イボシデニブの開発は、がん治療における分子標的治療の進展を象徴する事例です。従来の治療法では難治性とされる患者に対して、遺伝子変異に基づく特異的な治療が提供されることにより、より効果的な治療選択肢が増えることが期待されています。また、今後の研究によっては、IDH1変異以外のがんに対する応用も進む可能性があります。 関連技術としては、遺伝子解析技術があります。IDH1遺伝子の変異を検出するためには、次世代シーケンシング（NGS）やPCR（ポリメラーゼ連鎖反応）などの先進的な技術が利用されます。これらの技術によって、患者のがん細胞に特異的な遺伝子変異を早期に発見し、それに基づいて適切な治療を行うことが可能となります。このような個別化医療の進展は、今後のがん治療のパラダイムを大きく変えることが期待されています。 イボシデニブは、現在も臨床研究や新しい治療法の開発が進められており、他のがん治療薬との併用療法や、より効果的な治療法の探求が続いています。研究者たちは、イボシデニブ単独療法と他の療法の組み合わせによって、より高い奏効率を得ることを目指しており、これにより患者の治療成績の向上が図られることが期待されています。また、今後の研究結果により、イボシデニブが他のIDH変異を持つ腫瘍に対しても有効であることが示される可能性もあります。 今後のがん治療においては、より多様な選択肢が増えることで、患者一人ひとりの状況に応じた、より適切で効果的な治療が実現すると考えられています。イボシデニブの登場は、その先駆けとなるものであり、今後の治療の発展に寄与することが期待されています。患者の期待に応えるべく、研究者や医療従事者は引き続き努力を続けていくことでしょう。 |